N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial - Wikidata - wikimedia - TriplyDB

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial

http://www.wikidata.org/entity/Q36139749

about

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms Oxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus Erythematosus Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging Nitrosative stress and nitrated proteins in trichloroethene-mediated autoimmunity.Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia.Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus.The pathology of T cells in systemic lupus erythematosus Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus.N-Acetylcysteine protects against trichloroethene-mediated autoimmunity by attenuating oxidative stress Oxidative stress in the pathology and treatment of systemic lupus erythematosus HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE.Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus The role of neutrophils and NETosis in autoimmune and renal diseases.Oxidative stress, T cell DNA methylation, and lupus.Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review.Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.Systemic lupus erythematosus: review of synthetic drugs.T-cell metabolism in autoimmune disease.Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome.T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.Early-stage lupus nephritis treated with N-acetylcysteine: A report of two cases.Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin Significance of Lipid-Derived Reactive Aldehyde-Specific Immune Complexes in Systemic Lupus Erythematosus.Metabolic regulation of organelle homeostasis in lupus T cells N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease patients Redox homeostasis, T cells and kidney diseases: three faces in the dark.Interaction between glutathione and apoptosis in systemic lupus erythematosus.Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid.Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis.Updated review of complementary and alternative medicine treatments for systemic lupus erythematosus.Normalization of CD4+ T cell metabolism reverses lupus Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.Oxidative stress and its biomarkers in systemic lupus erythematosus.Environmental exposures, epigenetic changes and the risk of lupus.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.The comorbidity of ADHD and autism spectrum disorder.The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases.

P2860

Q26779929-1CB91C89-0780-4064-82A8-7ED6B99B8197 Q28071300-ABD2B2A0-028D-4E82-9188-9F7AFA2B90F6 Q28075691-6A1DBCEE-7B45-44FE-A0F7-FF31ECB6000A Q28081442-B7A1C812-0E91-415D-993F-B3E08FC9F758 Q31162430-FEAA21DC-15E5-4F84-8F4C-157B86C38C3B Q33412264-D2CF914E-3F74-4D41-A3F5-816EEECA5212 Q33424303-D8F613D1-A4B8-47AD-9B1C-F0222B2DB6D4 Q33598213-FDA435E5-409B-4A6F-8C15-37766CC9EB8F Q33664831-B9FA2E14-D928-4611-9053-4A5A3EB27C38 Q33675200-D62EF005-B797-488C-9C27-FAD9DAF02C9F Q33715508-4331FFC9-A480-408C-90E5-6E2BB2B8E17A Q33717763-0036D827-E226-4C44-B104-64AA999078F8 Q33722895-906A5902-979A-43FD-AF7F-953712A7FA24 Q33904653-E588BBAB-6027-43E0-AB5D-0FE214C02BE9 Q34077487-AF05EF05-CDA3-4C47-852C-E8F670258971 Q34351248-9AC92F5D-E7F3-4FA9-847B-566AE00F9488 Q34361763-47739100-CB57-4565-A6F9-467B13C92112 Q34498515-A85B1180-11E5-4C20-BF7F-14D23DEA9E22 Q35071556-0C8C5398-0FC8-41D0-8662-4912DB3D5788 Q35732790-D51F987C-D0DA-4DC4-B803-3BB9E1B2A924 Q35836112-B277A6E0-6DF7-43BA-A47F-8FD0D042CD18 Q35871258-18299963-78E5-429F-AE2E-329F4F0E2626 Q36024179-5E2B6FEB-74E0-439E-A10F-3DD8245116F6 Q36165313-FE92C992-4370-48FE-A1C2-840B89D946B5 Q36177195-DF2220F3-31D5-472B-A2BC-C75C62B4F0AF Q36296514-F2091118-AF54-410C-8D00-453601DC82F9 Q36482958-7DB9DD21-1319-4486-A75A-25DBEB8B7A21 Q36763234-E7270BBD-DD4F-4857-8A1C-9CD43AE66890 Q36823420-E48C090C-07DF-47B9-8746-FBDDEAD0C028 Q37357112-E5AA3087-EBC8-467B-A9F5-5E1592580038 Q37504605-C3CF6BE8-6CC4-4166-8466-BF8E51AC5F78 Q37625717-F1A08DB3-D979-4693-9EF8-5EB17FD477AF Q37649641-C5E15483-4E24-42AC-A646-FAC52B47DB86 Q37649687-0F323892-848D-4D86-87EF-FAD7EFDDC2EB Q37710586-ECC5F525-AAE9-433F-97E4-53990753ED8D Q37716274-4332F21D-14B4-4CB6-A595-9C4E522E8675 Q37724776-7D3FE018-C025-4820-AED4-33572F2CC54B Q38150110-B21C96D7-CCE2-4D98-ADB7-FFCA64BFFDE3 Q38151774-8FE7B141-D4B5-413D-B26A-16D2F0EC909D Q38322773-C8DA9ADB-496D-4B25-B339-74DE742A8633

P2860

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial

http://www.wikidata.org/entity/Q36139749

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

N-acetylcysteine reduces disea ...... lind, placebo-controlled trial

@ast

N-acetylcysteine reduces disea ...... lind, placebo-controlled trial

@en

type

label

N-acetylcysteine reduces disea ...... lind, placebo-controlled trial

@ast

N-acetylcysteine reduces disea ...... lind, placebo-controlled trial

@en

prefLabel

N-acetylcysteine reduces disea ...... lind, placebo-controlled trial

@ast

N-acetylcysteine reduces disea ...... lind, placebo-controlled trial

@en

P1433

Q36139749-DBB7F29A-E061-4300-B44E-4CEB75554F63

P1476

Q36139749-6CD01CF1-BBE5-45C0-AA34-61F254771A77

P2093

Q36139749-05D9CBE7-9FC9-42D8-BB96-F041C50A4D37

Q36139749-09B00DA2-C435-4689-80B2-E157CE78D5F8

Q36139749-0E150BF3-F943-444D-8056-C0FF2D918DAB

Q36139749-1061D10B-7DBF-428F-821B-C986E8AE1297

Q36139749-1F219A00-B896-4916-9A7B-F4231433BA01

Q36139749-21F60C64-C926-41CF-889B-B2F6B130C881

Q36139749-3CF16AD9-203C-4FAC-BEF2-3C7F5C469562

Q36139749-7441F1A3-33B5-445F-9166-DC4823965074

Q36139749-8A89B7D1-7456-4D2D-B05B-F8E6169087F6

Q36139749-8D5CF94E-0CAB-4C59-A8D6-F469EC0E58D0

P2860

Q36139749-0808B9A4-1576-4DFB-AC01-293167C5A458

Q36139749-14A00737-27DB-424A-AF1F-D8DA4746C177

Q36139749-2C3CB9E6-0188-4999-9294-D926B3BE4137

Q36139749-40BB8838-E4B1-4D01-B08F-823750181AFB

Q36139749-54BC5A8B-9641-4060-8E8A-F3008DD67E34

Q36139749-596F1743-DF46-44F6-921F-064A6DC60913

Q36139749-6ACEAE5C-FBDD-400B-A983-4AB98B596F25

Q36139749-6D19B501-51CE-420B-9BA5-856E8C7780B8

Q36139749-6D8F9604-0E1E-4A29-B8B0-E9E3D0218FD3

Q36139749-6EFE994C-4641-446A-BB40-1C11F6617F57

P304

Q36139749-EC93FB1D-7454-440C-B35A-CAE31FF5E0B1

P31

Q36139749-F97771BE-CED4-47ED-8370-6D0B63B7A2D9

P356

Q36139749-E359611A-606C-4EED-8637-9D1C4AD713B7

P433

Q36139749-CF115D48-9434-4A2C-8212-42DFD25CB5F4

P478

Q36139749-7B698EEB-BA61-4BB7-87D6-9DC74B0FBF58

P50

Q36139749-4E18C219-2DE3-40A0-8293-1EFC912BD56D

Q36139749-55000CE1-350F-4573-9650-04A15073D755

Q36139749-ACE0450B-B75B-4923-8194-2CE32CFFE803

P577

Q36139749-7DD3A7DC-7215-4310-97D4-EB48A469A63E

P5875

Q36139749-CE398ED9-82BE-4A92-9540-AC877A21CC90

P698

Q36139749-8E31BD3B-DCB6-4FB6-8055-2731C0FDD3DD

P921

Q36139749-8D2993E6-CD74-4AFE-9040-72119F35C03E

P932

Q36139749-B47F12A9-51A0-4A8A-BC92-62FE9B08D053

P356

P1433

Arthritis & Rheumatology

P1476

N-acetylcysteine reduces disea ...... lind, placebo-controlled trial

@en

P2093

Adam Bartos

http://www.w3.org/2001/XMLSchema#string

Brandon Clair

http://www.w3.org/2001/XMLSchema#string

Eduardo Bonilla

http://www.w3.org/2001/XMLSchema#string

Edward Doherty

http://www.w3.org/2001/XMLSchema#string

Gabriella Miklossy

http://www.w3.org/2001/XMLSchema#string

Hajra Tily

http://www.w3.org/2001/XMLSchema#string

Ioana Coman

http://www.w3.org/2001/XMLSchema#string

Irene Ramos

http://www.w3.org/2001/XMLSchema#string

Jianghong Yu

http://www.w3.org/2001/XMLSchema#string

Lisa Francis

http://www.w3.org/2001/XMLSchema#string

P2860

Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus

High-dose acetylcysteine in idiopathic pulmonary fibrosis

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Glutathione deficiency is associated with impaired survival in HIV disease.

Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells.

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

Modulation of endogenous glutathione availability.

mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?

Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.

Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys

P304

2937-2946

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.34502

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Faraone

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224878627

http://www.w3.org/2001/XMLSchema#string

P698

22549432

http://www.w3.org/2001/XMLSchema#string

P921

P932

3411859

http://www.w3.org/2001/XMLSchema#string